Table 7 Lung
Author | Cases N | Controlsa/Cohortb | Source Population | Exposure definition | Exposure assessment | Drug | RR | 95% CI |
|---|---|---|---|---|---|---|---|---|
Langman et al. [36] | 2,560 | 7,643a | Population based | >7 prescriptions during months 13–36 before index date | Automated Database | NSAIDs (7%) | 0.84 | 0.69–1.02 |
Harris et al. [51] | 489 | 978a | Hospital based | >7 tablets per week during more than 2 years | Personal Interview | NSAIDs(26%) | 0.32 | 0.23–0.44 |
Akhmedkhanov et al[54] | 81 | 808a | Population based‡ | >2 tablets per week during at least 6 months. 1 year lag time | Mailed Questionnaire | Aspirin (19%) | 0.66 | 0.34–1.28 |
Moysich et al. [55] | 868 | 935a | Hospital based | >1 tablet per week for at least 1 year | In hospital Questionnaire | Aspirin (18%) | 0.57 | 0.41–0.78 |
Rosenberg[56] | 1,110 | 4,906a | Hospital based | >3 days/week for >3 months 1.5 years of lag time | Personal Interview | NSAIDs (6%) | 1.0 | 0.7–1.4 |
Paganini-Hill et al. [40] | 111 | 13,987b | Cohort | Daily use of aspirin for an undefined time | Mailed Questionnaire | Aspirin (16%) | 0.92§ | 0.54–1.55 |
Thun et al. [46]†| NR men | 290,681b | Cohort | More than 16 times per month for at least one year | Mailed Questionnaire | Aspirin (11%) | 1.11 | 0.98–1.25 |
|  | NR women | 344,350b |  |  |  |  | 1.07 | 0.88–1.30 |
Schreinemachers et al. [43]†| 163 | 12,668b | Cohort | Ever use of aspirin in the 30 days prior to start date | Personal Interview | Aspirin (59%) | 0.68 | 0.49–0.94 |
-
Prevalence of exposure among controls/cohort; †Respiratory (includes others); §Crude estimate calculated from data provided in the original manuscript; ‡Female population.